API and Intermediate

Conivaptan hydrochloride

Product Name:Conivaptan hydrochloride
Synonyms:(1,1'-Biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride;Conivaptan HCl;Conivaptan hydrochloride [usan];Unii-75L57R6X36;Vaprisol;Conivaptan hydrochkoride;[1,1'-Biphenyl]-2-carboxamide,N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl]-,hydrochloride;Conivaptan hydrochloride, >=99%
CAS:168626-94-6
MF:C32H26N4O2.HCl
MW:535.04
EINECS:1312995-182-4
Product Categories:Aromatics;Intermediates & Fine Chemicals;Inhibitors;-;Pharmaceuticals
Mol File:168626-94-6.mol
Melting point:>250°
PSA:78.09000
LogP:7.44730
Boiling Point:751.2ºC at 760 mmHg
Flash Point:408.1ºC
Vapor Pressure:1.89E-22mmHg at 25°C
Type:Antidiuretic Hormone Receptor Antagonists, API
Grade:Pharma Grade
Appearance:White or off-white crystalline powder
Purity:99%
Package:500G;1KG;5KG;25KG For small quantity: Aluminium foil bag Commercial quantity: Aluminium foil bag
Handling and storage:Keep container tightly closed in a dry and well-ventilated place.Light sensitive.
Place of Origin:China
Description:Arginine vasopressin is intimately involved in volume homeostasis, and elevated levels of arginine vasopressin are responsible for the pathogenesis and progression of diseases with an imbalance of sodium and water, particularly congestive heart failure. To restore homeostasis, antagonism of vasopressin receptors is a practical solution. As such, conivaptan has been developed and launched as a dual V1a and V2 vasopressin receptor antagonist. As a competitive, reversible inhibitor of both subtypes, conivaptan can modulate systemic vascular resistance through the V1a receptor (Ki ? 0.48 nM) distributed in vascular smooth muscle cells, cardiomyocytes, hepatocytes, and platelets and blocks the renal V2 receptor (Ki ? 3.04 nM) resulting in enhanced diuresis, thereby increasing serum sodium concentration and reducing total body volume. Currently, the drug is approved for the management of refractory hyponatremia and potentially lifethreatening sodium and water imbalance, but it has shown promise as a potential treatment option for other diseases, such as congestive heart failure, syndrome of antidiuretic hormone, diabetes insipidus, and liver cirrhosis.
Uses:Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist).

Copyright(C)2017, KangRui BIO-TECH Co.,Ltd.(H.K.) All Rights Reserved. Supported by ChinaTexNet TexWeb Toocle Backstage 备案号:浙ICP备09104425号-1
 
点击这里给我发消息
点击这里给我发消息
 
 
 
 
 
My status
David Chen
My status
biopharmonline